BioChaperone PDGF (BC PDGF) fails Phase III trial in the treatment of diabetic foot ulcer.- Adocia
Adocia announced topline results from a Phase III clinical trial of BioChaperone PDGF (BC PDGF) in the treatment of diabetic foot ulcer (DFU), which was conducted in India. In this trial, BC PDGF did not meet the primary endpoint of a statistically significant improvement over placebo in complete wound closure after twenty weeks of treatment. There were no safety concerns attributed to BC PDGF.
" We are surprised and disappointed by these topline results, which are inconsistent with previously reported positive Phase 1/II clinical results. Therefore, we have initiated a thorough review of the study to analyse the discrepancy in the data� said G�rard Soula, CEO of Adocia. �However, diabetic foot ulcer has proved an extremely difficult condition to address, as seen in multiple recent late-stage clinical trial failures. The main reason is the lack of uniformity in the standard of care of these types of wounds. In this context, we have decided to halt all development work in this indication".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins